CLBT

Cellebrite DI Ltd. (CLBT) | Rumor.io

Cellebrite DI

CLBT

Attention (50-day avg)0%

Attention rank (50-day avg)#1,093

Bullish sentiment (50-day avg)49%

Price to earnings ratio46.1

Market capitalization2.8B

Earnings per share0.24

Dividend yield (TTM)—

Revenue (annual)475.7M

Net income (annual)78.3M

Social

What share of all stock conversation is about CLBT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 17

Cellebrite's (CLBT) stock price fell 30% after a poor earnings report, with the CEO also announcing their departure.
The company's earnings call provided some positive hints, including new deals and a delay of about 6 weeks, which may lead to a decent price increase in Q3.
Despite the recent decline, the stock is considered undervalued and has robust fundamentals, making it an attractive buy at current levels.

Generated by AI

Sentiment

Of the messages about CLBT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100%	100% +72.2	79.28% -8.11
Bearish	0% 0	0%	0% -72.2	20.72% +8.11

Bullish· Nov 13

Cellebrite DI's Q3 2025 financial results exceeded expectations, with adjusted EPS of $0.14, revenue of $126.0M, and net income of $20.2M.
The company's ARR grew 19% YoY to $439.8M, demonstrating the success of its SaaS pivot and positioning $CLBT as a high-margin software play.
Analysts are increasingly bullish on $CLBT, with B of A Securities upgrading its rating to Buy and setting a price target of $25, and JP Morgan raising its target price.

Bearish· Aug 13

The CEO of Cellebrite DI Ltd. (CLBT) has been replaced, and the company has cut its full-year 2026 revenue guidance.
The company's Q3 guidance missed consensus, and the CEO's departure has led to a significant sell-off, with the stock down 31% to a new 52-week low.
Cellebrite's management has been criticized for their handling of the situation, with analysts expressing concern on the company's conference call and the stock's price dropping further, with one analyst stating it's now a "show me story".

Generated by AI

Topics

Of the messages about CLBT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	62.96%	71.43%	38.08%
Controversies	50%	29.63%	18.68%	27.77%
Technical Analysis	0%	7.41%	9.89%	3.23%
Earnings	0%	0%	0%	19.12%
Analysts	0%	0%	0%	5.23%
Macro	0%	0%	0%	6.56%

Earnings· Aug 13

Cellebrite DI Ltd.'s Q2 2026 earnings report revealed a 30% drop in the stock price, primarily due to lower revenue guidance and the sudden CEO replacement.
The company's CEO, Tom Hogan, stepped down and was replaced by Shiven Ramji, who cited "elongated sales cycles" for the lowered full-year 2026 revenue guidance.
Cellebrite's Q2 2026 earnings beat on EPS, but the company's adjusted EBITDA guidance was raised despite missing Q3 guidance, and the stock price fell to a new 52-week low due to the guidance cut.

Announcements· May 14

Cellebrite DI Ltd. reported Q1 revenue of $128.3M, up 19% year-over-year, with subscription revenue up 23% and total ARR rising 21% to $493.0M.
The company's strategic expansion and AI-powered software-as-a-service offerings are unlocking massive growth potential, with a 32% free cash flow margin and a 115% recurring revenue dollar-based net retention rate.
Cellebrite's new AI platform, Genesis, has seen rapid adoption, with over 500 registered users across 15 countries, and is expected to challenge other companies in the digital intelligence sector.

Controversies· Aug 17

Cellebrite DI Ltd.'s CEO was replaced after a 30% drop in stock price following a disappointing earnings report, sparking allegations of insider trading.
Several insiders sold Cellebrite stock the day before the earnings report, which also included the CEO selling millions of dollars worth of shares.
The incident raises questions about the legitimacy of the trades and the potential involvement of the SEC in investigating these alleged insider trading activities.

Generated by AI

Community

Of the messages about CLBT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	92.86%	37.78%	47.06%	34.96%
Newcomers	7.14%	62.22%	52.94%	65.04%

Regulars· Aug 13

The CEO change and lower revenue guidance have hit the stock hard, but some regulars think the situation is not as bad as the 30% drop suggests, with the big issue being the company's supposed strong year in 2026 driven by new products.
The sudden CEO replacement accompanied by a significant cut to the company's full-year ARR and revenue guidance has derailed the hyper-growth narrative, with some regulars noting that the CEO sold stock via Form 144 just before earnings and that the company's guidance cut is more severe than expected.
The stock is getting crushed post-earnings, with a -36% drop, and some regulars are questioning the management's performance, with one stating that it appears there's a leadership problem and another that the company is preparing the ground to be acquired.

Newcomers· Aug 17

The stock fell 30% after a poor earnings report, dropping to the 10-11 range from 15-16, and the CEO was replaced, with several insiders selling before the announcement.
The newcomer is enthusiastic about the stock's fundamentals and valuation at current levels, calling it "yummy".
The stock is currently a top loser in a stock screener, with a price of 10.45 and a high volume of 3.1M.

Generated by AI

News

Kaplan Fox Advises Investors of Cellebrite DI Ltd. (NASDAQ: CLBT) of an Investigation Into Potential Securities Law Violations

15h agoBarchart.com

Cellebrite's 2026 Outlook: Subscription Pivot Weighs on the Stock Today, Helps Lead a Future Rebound | The Motley Fool

This under-the-radar cybersecurity stock boasts a Superscore of 79 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

18h agoThe Motley Fool

Kaplan Fox Notifies Cellebrite DI Ltd. (NASDAQ: CLBT) Investors of an Investigation Into Possible Securities Law Violations

5d agoBarchart.com

Cellebrite Calls for 2027 JUSTYS Nominees, Premier Event Highlights Unsung Heroes Who Keep the World Safe

6d agoMorningstar

Is Cellebrite DI (CLBT) A Bargain On Its Subscription Growth Narrative?

Cellebrite DI (CLBT) sits in focus after recent share performance left the stock down over the past year, despite revenue of US$514.289m and net income of US$58.246m from its digital investigations platform. Cellebrite DI’s share price has slipped over recent months, with the stock down 35.2% year to date and 9.26% over the past quarter, even though the 30 day share price return of 4.62% shows a short burst of positive momentum against a weaker near term trend. Scan beyond Cellebrite DI and...

8d agoYahoo Finance

Kaplan Fox Encourages Cellebrite DI Ltd. (NASDAQ: CLBT) Investors to Contact the Firm Regarding an Ongoing Securities Investigation

Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

8d agoThe Globe and Mail

Also Discussed

Investors talking about CLBT also mention

#	Name	Attention
1	Open Lending CorporationLPRO	0%new
2	Lifecore Biomedical Inc.LFCR	0%-0.01
3	enGene Therapeutics Inc.ENGN	0%0
4	Angel Oak UltraShort Income FundUYLD	0%0
5	WEBs QQQ Defined Volatility ETFDVQQ	0%0
6	Super Group (SGHC) LimitedSGHC	0%0
7	Oaktree Acquisition Corp. IIIOACCU	0%0
8	Global X Clean Water ETFAQWA	0%0
9	N-able Inc.NABL	0%0
10	Cognyte Software Ltd.CGNT	0%new

Cellebrite DI Ltd.

Technology
Software - Infrastructure

Cellebrite DI Ltd. is a digital intelligence software company that provides tools for legally sanctioned investigations across public and private sector environments. Cellebrite DI Ltd. offers a platform used to access, collect, review, extract, decode, decrypt, analyze, share, and manage digital evidence throughout the investigative process. Its products and services support law enforcement, government agencies, and enterprise customers handling complex cases involving mobile devices, cloud data, and other digital sources. The company also provides training, advisory, advanced services, and technical support to help customers use its investigative workflows effectively. Cellebrite DI Ltd. serves a broad range of use cases, including cybercrime, financial crime, organized crime, counterterrorism, border control, and corporate investigations, making it an important provider in the digital forensics and investigative technology market.

Website

Location

94 Shlomo Shmelzer Road

Petah Tikva, 4970602

Israel

Social

What share of all stock conversation is about CLBT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 17

Cellebrite's (CLBT) stock price fell 30% after a poor earnings report, with the CEO also announcing their departure.
The company's earnings call provided some positive hints, including new deals and a delay of about 6 weeks, which may lead to a decent price increase in Q3.
Despite the recent decline, the stock is considered undervalued and has robust fundamentals, making it an attractive buy at current levels.

Generated by AI

Sentiment

Of the messages about CLBT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100%	100% +72.2	79.28% -8.11
Bearish	0% 0	0%	0% -72.2	20.72% +8.11

Bullish· Nov 13

Cellebrite DI's Q3 2025 financial results exceeded expectations, with adjusted EPS of $0.14, revenue of $126.0M, and net income of $20.2M.
The company's ARR grew 19% YoY to $439.8M, demonstrating the success of its SaaS pivot and positioning $CLBT as a high-margin software play.
Analysts are increasingly bullish on $CLBT, with B of A Securities upgrading its rating to Buy and setting a price target of $25, and JP Morgan raising its target price.

Bearish· Aug 13

The CEO of Cellebrite DI Ltd. (CLBT) has been replaced, and the company has cut its full-year 2026 revenue guidance.
The company's Q3 guidance missed consensus, and the CEO's departure has led to a significant sell-off, with the stock down 31% to a new 52-week low.
Cellebrite's management has been criticized for their handling of the situation, with analysts expressing concern on the company's conference call and the stock's price dropping further, with one analyst stating it's now a "show me story".

Generated by AI

Topics

Of the messages about CLBT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	62.96%	71.43%	38.08%
Controversies	50%	29.63%	18.68%	27.77%
Technical Analysis	0%	7.41%	9.89%	3.23%
Earnings	0%	0%	0%	19.12%
Analysts	0%	0%	0%	5.23%
Macro	0%	0%	0%	6.56%

Earnings· Aug 13

Cellebrite DI Ltd.'s Q2 2026 earnings report revealed a 30% drop in the stock price, primarily due to lower revenue guidance and the sudden CEO replacement.
The company's CEO, Tom Hogan, stepped down and was replaced by Shiven Ramji, who cited "elongated sales cycles" for the lowered full-year 2026 revenue guidance.
Cellebrite's Q2 2026 earnings beat on EPS, but the company's adjusted EBITDA guidance was raised despite missing Q3 guidance, and the stock price fell to a new 52-week low due to the guidance cut.

Announcements· May 14

Cellebrite DI Ltd. reported Q1 revenue of $128.3M, up 19% year-over-year, with subscription revenue up 23% and total ARR rising 21% to $493.0M.
The company's strategic expansion and AI-powered software-as-a-service offerings are unlocking massive growth potential, with a 32% free cash flow margin and a 115% recurring revenue dollar-based net retention rate.
Cellebrite's new AI platform, Genesis, has seen rapid adoption, with over 500 registered users across 15 countries, and is expected to challenge other companies in the digital intelligence sector.

Controversies· Aug 17

Cellebrite DI Ltd.'s CEO was replaced after a 30% drop in stock price following a disappointing earnings report, sparking allegations of insider trading.
Several insiders sold Cellebrite stock the day before the earnings report, which also included the CEO selling millions of dollars worth of shares.
The incident raises questions about the legitimacy of the trades and the potential involvement of the SEC in investigating these alleged insider trading activities.

Generated by AI

Community

Of the messages about CLBT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	92.86%	37.78%	47.06%	34.96%
Newcomers	7.14%	62.22%	52.94%	65.04%

Regulars· Aug 13

The CEO change and lower revenue guidance have hit the stock hard, but some regulars think the situation is not as bad as the 30% drop suggests, with the big issue being the company's supposed strong year in 2026 driven by new products.
The sudden CEO replacement accompanied by a significant cut to the company's full-year ARR and revenue guidance has derailed the hyper-growth narrative, with some regulars noting that the CEO sold stock via Form 144 just before earnings and that the company's guidance cut is more severe than expected.
The stock is getting crushed post-earnings, with a -36% drop, and some regulars are questioning the management's performance, with one stating that it appears there's a leadership problem and another that the company is preparing the ground to be acquired.

Newcomers· Aug 17

The stock fell 30% after a poor earnings report, dropping to the 10-11 range from 15-16, and the CEO was replaced, with several insiders selling before the announcement.
The newcomer is enthusiastic about the stock's fundamentals and valuation at current levels, calling it "yummy".
The stock is currently a top loser in a stock screener, with a price of 10.45 and a high volume of 3.1M.

Generated by AI

Cellebrite DI

Social

Aug 17

Bullish· Nov 13

Bearish· Aug 13

Earnings· Aug 13

Announcements· May 14

Controversies· Aug 17

Regulars· Aug 13

Newcomers· Aug 17

Kaplan Fox Advises Investors of Cellebrite DI Ltd. (NASDAQ: CLBT) of an Investigation Into Potential Securities Law Violations

Cellebrite's 2026 Outlook: Subscription Pivot Weighs on the Stock Today, Helps Lead a Future Rebound | The Motley Fool

Kaplan Fox Notifies Cellebrite DI Ltd. (NASDAQ: CLBT) Investors of an Investigation Into Possible Securities Law Violations

Cellebrite Calls for 2027 JUSTYS Nominees, Premier Event Highlights Unsung Heroes Who Keep the World Safe

Is Cellebrite DI (CLBT) A Bargain On Its Subscription Growth Narrative?

Kaplan Fox Encourages Cellebrite DI Ltd. (NASDAQ: CLBT) Investors to Contact the Firm Regarding an Ongoing Securities Investigation

Also Discussed

Cellebrite DI Ltd.

Company Information

Location

Kaplan Fox Advises Investors of Cellebrite DI Ltd. (NASDAQ: CLBT) of an Investigation Into Potential Securities Law Violations

Cellebrite's 2026 Outlook: Subscription Pivot Weighs on the Stock Today, Helps Lead a Future Rebound | The Motley Fool

Kaplan Fox Notifies Cellebrite DI Ltd. (NASDAQ: CLBT) Investors of an Investigation Into Possible Securities Law Violations

Cellebrite Calls for 2027 JUSTYS Nominees, Premier Event Highlights Unsung Heroes Who Keep the World Safe

Is Cellebrite DI (CLBT) A Bargain On Its Subscription Growth Narrative?

Kaplan Fox Encourages Cellebrite DI Ltd. (NASDAQ: CLBT) Investors to Contact the Firm Regarding an Ongoing Securities Investigation

Also Discussed

Social

Aug 17

Bullish· Nov 13

Bearish· Aug 13

Earnings· Aug 13

Announcements· May 14

Controversies· Aug 17

Regulars· Aug 13

Newcomers· Aug 17